Novo, Mylan Seek Judgment on Key Wegovy Patent Before Trial

Novo Nordisk A/S and Viatris Inc.’s Mylan unit asked a Delaware federal court to formalize Mylan’s concession that its generic Wegovy injection infringes Novo’s compound patent, an agreement that would block the copy until at least December 2031.

The proposed judgment would resolve allegations over US Patent No. 8,129,343, which covers the semaglutide compound in Novo’s weight-loss drug. That would narrow the case to three later-expiring patents covering formulations of Wegovy’s active ingredient and dosing methods.

A bench trial slated for March was scrapped last month, and the companies have been sparring over when the remaining patents should be ...